Parkside Financial Bank & Trust Buys 2,358 Shares of Evolent Health, Inc. (NYSE:EVH)

Parkside Financial Bank & Trust boosted its stake in shares of Evolent Health, Inc. (NYSE:EVH) by 90.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,957 shares of the technology company’s stock after acquiring an additional 2,358 shares during the period. Parkside Financial Bank & Trust’s holdings in Evolent Health were worth $56,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in EVH. Wellington Management Group LLP increased its position in shares of Evolent Health by 12.8% in the third quarter. Wellington Management Group LLP now owns 12,595,459 shares of the technology company’s stock worth $356,200,000 after purchasing an additional 1,426,747 shares during the period. Eventide Asset Management LLC grew its stake in Evolent Health by 1.7% during the third quarter. Eventide Asset Management LLC now owns 3,804,104 shares of the technology company’s stock worth $107,580,000 after buying an additional 64,985 shares in the last quarter. State Street Corp increased its holdings in Evolent Health by 1.0% in the 3rd quarter. State Street Corp now owns 2,725,375 shares of the technology company’s stock valued at $77,074,000 after buying an additional 25,967 shares during the period. Bellevue Group AG raised its position in shares of Evolent Health by 59.9% in the 3rd quarter. Bellevue Group AG now owns 2,670,050 shares of the technology company’s stock valued at $75,509,000 after buying an additional 1,000,215 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Evolent Health by 1,948.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,495,385 shares of the technology company’s stock worth $42,289,000 after acquiring an additional 1,422,385 shares during the period.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on EVH. Needham & Company LLC reissued a “buy” rating and issued a $15.00 price objective on shares of Evolent Health in a research note on Friday, February 21st. Piper Sandler reiterated an “overweight” rating and issued a $16.00 price target (down previously from $17.00) on shares of Evolent Health in a research note on Friday, February 21st. Citigroup dropped their price objective on Evolent Health from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Friday, January 10th. JPMorgan Chase & Co. decreased their target price on Evolent Health from $15.00 to $13.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Finally, Canaccord Genuity Group dropped their target price on shares of Evolent Health from $23.00 to $16.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. One equities research analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Evolent Health currently has a consensus rating of “Buy” and a consensus price target of $17.79.

Evolent Health Trading Down 2.0 %

EVH opened at $8.81 on Tuesday. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04. Evolent Health, Inc. has a fifty-two week low of $8.40 and a fifty-two week high of $35.00. The company’s 50 day moving average price is $10.56 and its two-hundred day moving average price is $18.14. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of -10.74 and a beta of 1.45.

Evolent Health (NYSE:EVH) last issued its quarterly earnings data on Thursday, February 20th. The technology company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.38 by ($0.35). The business had revenue of $646.54 million during the quarter, compared to the consensus estimate of $650.92 million. Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. As a group, research analysts predict that Evolent Health, Inc. will post 0.08 earnings per share for the current year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.